biostudies-literatureUnknown11(15)Abolhalaj MVetenskapsrådetLunds Tekniska Högskola, Lunds universitetMats Paulssons StiftelseVINNOVAFondation ISRECCancerfonden<h4>Background</h4>Acute myeloid leukemia (AML) patients have limited effect from T-cell-based therapies, such as PD-1 and CTLA-4 blockade. However, recent data indicate that AML patients with TP53 mutation have higher immune infiltration and other immunomodulatory therapies could thus potentially be effective. Here, we performed the transcriptional analysis of distinct T-cell subpopulations from TP53-mutated AML to identify gene expression signatures suggestive of altered functional properties.<h4>Methods</h4>CD8⁺ cytotoxic T lymphocytes (CTLs), conventional helper T cells (Th), and regulatory T cells (Tregs) were sorted from peripheral blood of AML patients with TP53 mutation (n = 5) and healthy donors (n = 3), using FACS, and the different subpopulations were subsequently subCancer medicine3023-3032https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359873biostudies-literatureTranscriptional profiling demonstrates altered characteristics of CD8⁺ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.PMC9359873Hagerbrand KSincic VAab AFioretos TSanden CBorrebaeck CAKLundberg KAbolhalaj MEllmark PLilljebjorn HfalseTranscriptional profiling demonstrates altered characteristics of CD8⁺ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.<h4>Background</h4>Acute myeloid leukemia (AML) patients have limited effect from T-cell-based therapies, such as PD-1 and CTLA-4 blockade. However, recent data indicate that AML patients with TP53 mutation have higher immune infiltration and other immunomodulatory therapies could thus potentially be effective. Here, we performed the transcriptional analysis of distinct T-cell subpopulations from TP53-mutated AML to identify gene expression signatures suggestive of altered functional properties.<h4>Methods</h4>CD8⁺ cytotoxic T lymphocytes (CTLs), conventional helper T cells (Th), and regulatory T cells (Tregs) were sorted from peripheral blood of AML patients with TP53 mutation (n = 5) and healthy donors (n = 3), using FACS, and the different subpopulations were subsequently sub2022-01-01T00:00:00Z2022 Aug2026-03-31T11:22:13.576Z2025-04-04T19:27:39.143ZS-EPMC93598733529721310.1002/cam4.4661